{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:36:40Z","timestamp":1790761000007,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jaccao.2022.08.011","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:24Z","timestamp":1668556824000},"page":"474-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis"],"prefix":"10.1016","volume":"4","author":[{"given":"Monique C.","family":"Minnema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Comenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh D.","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NamPhuong","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Y.","family":"Vasey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jaccard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2022.08.011_bib1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar","year":"2020","journal-title":"J\u00a0Intern Med"},{"issue":"4","key":"10.1016\/j.jaccao.2022.08.011_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11899-013-0175-0","article-title":"New insights and modern treatment of AL amyloidosis","volume":"8","author":"Chaulagain","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"10.1016\/j.jaccao.2022.08.011_bib3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.jaccao.2022.08.011_bib4","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A\u00a0European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jaccao.2022.08.011_bib5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/14779072.2015.1093936","article-title":"Novel strategies for the diagnosis and treatment of cardiac amyloidosis","volume":"13","author":"Palladini","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"10.1016\/j.jaccao.2022.08.011_bib6","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jaccao.2022.08.011_bib7","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaccao.2022.08.011_bib8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000508287","article-title":"Prognosis and staging of AL amyloidosis","volume":"143","author":"Dittrich","year":"2020","journal-title":"Acta Haematol"},{"issue":"14","key":"10.1016\/j.jaccao.2022.08.011_bib9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan","year":"2017","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.jaccao.2022.08.011_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","article-title":"Natural history and therapy of AL cardiac amyloidosis","volume":"20","author":"Grogan","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"5","key":"10.1016\/j.jaccao.2022.08.011_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/heartjnl-2013-304957","article-title":"High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis","volume":"100","author":"Dispenzieri","year":"2014","journal-title":"Heart"},{"issue":"25","key":"10.1016\/j.jaccao.2022.08.011_bib12","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A\u00a0prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.jaccao.2022.08.011_bib13","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaccao.2022.08.011_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood","year":"2014","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.jaccao.2022.08.011_bib15","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.011_bib16","doi-asserted-by":"crossref","unstructured":"Palladini G, Sch\u00f6nland S, Merlini G, Milani P. First glimpse on real-world efficacy outcomes for 2000 patients with systemic light chain amyloidosis in Europe: a retrospective observational multicenter study by the European Myeloma Network. Presented at: American Society of Hematology Annual Meeting; December 5-8,\u00a02020.","DOI":"10.1182\/blood-2020-140708"},{"issue":"1","key":"10.1016\/j.jaccao.2022.08.011_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.08.011_bib18","series-title":"Darzalex Faspro\u2122 (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use [prescribing information]","year":"2020"},{"issue":"1","key":"10.1016\/j.jaccao.2022.08.011_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","article-title":"Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis","volume":"28","author":"Palladini","year":"2021","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.jaccao.2022.08.011_bib20","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.jaccao.2022.08.011_bib21","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A\u00a0staging system for renal outcome and early markers of renal response to chemotherapy in\u00a0AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.08.011_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-3-319-40320-5_15","article-title":"Immunoglobulin light chain systemic amyloidosis","volume":"169","author":"Dispenzieri","year":"2016","journal-title":"Cancer Treat Res"},{"issue":"9","key":"10.1016\/j.jaccao.2022.08.011_bib23","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","article-title":"Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)","volume":"99","author":"Jaccard","year":"2014","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.jaccao.2022.08.011_bib24","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10192","key":"10.1016\/j.jaccao.2022.08.011_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"10218","key":"10.1016\/j.jaccao.2022.08.011_bib26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.jaccao.2022.08.011_bib27","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jaccao.2022.08.011_bib28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/cells10030545","article-title":"Daratumumab in the treatment of light-chain (AL) amyloidosis","volume":"10","author":"Palladini","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.jaccao.2022.08.011_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive review of AL amyloidosis: some practical recommendations","volume":"11","author":"Al Hamed","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaccao.2022.08.011_bib30","unstructured":"Kastritis E. Subcutaneous daratumumab\u00a0+ cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed light chain (AL) amyloidosis: primary results from the phase 3 ANDROMEDA study. Presented at: EHA25 Virtual Congress; June 11-21,\u00a02020."}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322003957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322003957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:55:47Z","timestamp":1762973747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087322003957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2666087322003957"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.011","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}